A claims-based Markov model for Crohn's disease

19Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aliment Pharmacol Ther 2010; 32: 448-458 SummaryBackground Crohn's disease is a chronic condition that often presents in early adulthood. Aim To evaluate health care costs and costs per quality-adjusted life year (QALY) for Crohn's disease. Methods A Markov model was developed using administrative claims data for patients aged ≥ 18 years with ≥ 3 years of continuous enrolment from 2000 to 2008 and ≥2 Crohn's disease claims. Disease states (remission, mild-moderate, moderate-severe, and severe-fulminant) were defined using the American College of Gastroenterology treatment guidelines criteria. Transition probabilities were calculated from consecutive 6-month periods. Costs were determined from paid claims and QALY utilities were obtained from the literature. The model assumed a 30-year-old patient at the time of entry into the model. Results There were 40 063 patients identified, with a total of 420 773 cycles [remission (197 111; 46.8%), mild-moderate (44 024; 10.5%), moderate-severe (132 695; 31.5%), severe-fulminant (46 925; 11.2%)]. The costsQALY for remission, mild-moderate, moderate-severe, and severe-fulminant disease states respectively were $2896, $8428, $11 518 and $69 277 for males and $2896, $8426, $22 633 and $69 412 for females. Conclusions Overall, health care costs for patients with Crohn's disease increased with disease severity. Although the probabilities of transitioning from other health states to the severe-fulminant disease state were low, the costQALY was high. © 2010 Blackwell Publishing Ltd.

References Powered by Scopus

Predictability of the postoperative course of Crohn's disease

1613Citations
N/AReaders
Get full text

The Prevalence and Geographic Distribution of Crohn's Disease and Ulcerative Colitis in the United States

817Citations
N/AReaders
Get full text

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

638Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A Test-based strategy is more cost effective than empiric dose escalation for patients with crohn's disease who lose responsiveness to infliximab

169Citations
N/AReaders
Get full text

Truven Health Analytics MarketScan Databases for Clinical Research in Colon and Rectal Surgery

89Citations
N/AReaders
Get full text

Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis

64Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Malone, D. C., Waters, H. C., Van Den Bos, J., Popp, J., Draaghtel, K., & Rahman, M. I. (2010). A claims-based Markov model for Crohn’s disease. Alimentary Pharmacology and Therapeutics, 32(3), 448–458. https://doi.org/10.1111/j.1365-2036.2010.04356.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 21

64%

Researcher 7

21%

Professor / Associate Prof. 5

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

62%

Economics, Econometrics and Finance 4

15%

Social Sciences 3

12%

Psychology 3

12%

Save time finding and organizing research with Mendeley

Sign up for free